GICS Sector : Healthcare
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally.
CVRx reported a strong financial performance for the fourth quarter and full year 2025, with revenue reaching $16 million and $56.7 million, respectively, representing a 410% growth for the full year. The company's gross margin was above expectations, although the exact figure was not disclosed. The earnings per share (EPS) came in at -$0.46, slightly below estimates of -$0.42. The company's financial performance was driven by the successful execution of its strategic priorities, including building a world-class sales organization and driving deep adoption in targeted centers.
Publication Date: Mar -05
The company made significant progress in advancing its Barostim therapy, with the sales organization expanding to 53 territories and 252 active implanting centers, up 10% and 13%, respectively. The transition to Category I CPT codes, effective January 1, 2026, is expected to improve reimbursement and drive adoption. Additionally, the company secured approval and coverage for the landmark BENEFIT HF trial, which will evaluate the impact of Barostim on all-cause mortality and heart failure decompensation events in an expanded population. As Kevin Hykes noted, "The initiation of the BENEFIT HF trial represents one of the most significant developments in our company's history."
For the full year 2026, CVRx expects total revenue between $63 million and $67 million, representing growth of 11% to 18%. The company expects gross margin between 84% and 86% and operating expenses between $103 million and $107 million. Analysts estimate next year's revenue growth at 18.4%, which is slightly above the company's guidance. The company's cash reserves and access to nondilutive capital provide a solid financial foundation, with $86 million in the bank and an additional $40 million available through a debt amendment.
CVRx's valuation metrics indicate a high-growth profile, with a Price-to-Sales Ratio of 3.94 and an EV/EBITDA of -4.17. The company's P/E Ratio is -4.18, reflecting its current loss-making status. The ROE and ROIC are also negative, at -99.33% and -56.04%, respectively. With a significant addressable market and a strong pipeline, the company's growth prospects are promising, but investors should be cautious about the risks associated with the trial and the competitive landscape.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Mar -03
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
Mar -02
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Feb -26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Feb -24
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Feb -20
CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Feb -19
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Feb -19
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Feb -19
CVRx, Inc.'s medical device growth is driven by increasing demand for minimally invasive treatments, rising prevalence of hypertension and heart failure, growing adoption of Barostim Neo device, and expanding reimbursement coverage. Additionally, strategic partnerships and investments in clinical trials are fueling innovation and market expansion, contributing to the 8.74% growth rate.
A minimally invasive, implantable device that uses the power of the body's natural baroreceptor mechanism to provide a unique, long-term treatment for hypertension and heart failure.
A device that uses the same technology as Barostim Neo, but is designed for patients who require a more compact device.
CVRx, Inc. has a unique technology that is not easily substitutable, reducing the threat of substitutes.
CVRx, Inc. has a diverse customer base, but some large customers may have bargaining power due to their size and purchasing power.
CVRx, Inc. has a diverse supplier base, reducing the bargaining power of individual suppliers.
The medical device industry is highly competitive, and new entrants may pose a significant threat to CVRx, Inc.'s market share.
The medical device industry is highly competitive, and CVRx, Inc. faces intense rivalry from established companies and new entrants.
| Value | |
|---|---|
| Debt Weight | 28.73% |
| Debt Cost | 3.95% |
| Equity Weight | 71.27% |
| Equity Cost | 10.37% |
| WACC | 8.53% |
| Leverage | 40.31% |
Value: 8.4
Growth: 6.4
Quality: 5.2
Yield: 0.0
Momentum: 5.0
Volatility: 3.3
1-Year Total Return ->
Value: 9.8
Growth: 7.7
Quality: 3.3
Yield: 0.0
Momentum: 0.0
Volatility: 0.7
1-Year Total Return ->
Value: 9.8
Growth: 5.0
Quality: 4.5
Yield: 0.0
Momentum: 1.0
Volatility: 0.7
1-Year Total Return ->
Value: 7.8
Growth: 4.7
Quality: 3.9
Yield: 0.0
Momentum: 2.0
Volatility: 1.3
1-Year Total Return ->
Value: 7.0
Growth: 4.7
Quality: 3.9
Yield: 0.0
Momentum: 1.5
Volatility: 1.3
1-Year Total Return ->
Value: 6.6
Growth: 2.2
Quality: 2.4
Yield: 0.0
Momentum: 5.5
Volatility: 1.0
1-Year Total Return ->